BRPI0515168A - 7-azaindóis, processos para sua preparação e seu uso como fármacos - Google Patents
7-azaindóis, processos para sua preparação e seu uso como fármacosInfo
- Publication number
- BRPI0515168A BRPI0515168A BRPI0515168-6A BRPI0515168A BRPI0515168A BR PI0515168 A BRPI0515168 A BR PI0515168A BR PI0515168 A BRPI0515168 A BR PI0515168A BR PI0515168 A BRPI0515168 A BR PI0515168A
- Authority
- BR
- Brazil
- Prior art keywords
- processes
- azaindoles
- disorders
- pharmaceuticals
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04021667 | 2004-09-11 | ||
| PCT/EP2005/009269 WO2006029699A1 (en) | 2004-09-11 | 2005-08-27 | 7-azaindoles and their use as ppar agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0515168A true BRPI0515168A (pt) | 2008-07-08 |
Family
ID=34926507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0515168-6A BRPI0515168A (pt) | 2004-09-11 | 2005-08-27 | 7-azaindóis, processos para sua preparação e seu uso como fármacos |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7541464B2 (enExample) |
| EP (1) | EP1794159B1 (enExample) |
| JP (1) | JP2008512408A (enExample) |
| KR (1) | KR20070053243A (enExample) |
| CN (1) | CN101018790A (enExample) |
| AU (1) | AU2005284485A1 (enExample) |
| BR (1) | BRPI0515168A (enExample) |
| CA (1) | CA2580135A1 (enExample) |
| IL (1) | IL181560A0 (enExample) |
| MX (1) | MX2007002689A (enExample) |
| WO (1) | WO2006029699A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101272784A (zh) | 2005-09-29 | 2008-09-24 | 塞诺菲-安万特股份有限公司 | 苯基-和吡啶基-1,2,4-噁二唑酮衍生物、它们的制备方法和它们作为药物的用途 |
| PE20080188A1 (es) * | 2006-04-18 | 2008-03-10 | Janssen Pharmaceutica Nv | Derivados del acido benzoazepin-oxi-acetico como agonistas de ppar-delta usados para aumentar hdl-c, reducir ldl-c y reducir colesterol |
| RU2009108280A (ru) | 2006-08-08 | 2010-09-20 | Санофи-Авентис (Fr) | Ариламиноарилалкилзамещенные имидазолидин-2,4-дионы, способы их получения, содержащие эти соединения лекарственные средства и их применение |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE102007054497B3 (de) | 2007-11-13 | 2009-07-23 | Sanofi-Aventis Deutschland Gmbh | Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung |
| EP2310372B1 (en) | 2008-07-09 | 2012-05-23 | Sanofi | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| MX2012001729A (es) | 2009-08-26 | 2012-06-13 | Sanofi Sa | Nuevos hidratos cristalinos de fluoroglicosido heteroaromatico, productos farmaceuticos que comprenden estos compuestos, y su empleo. |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| US8901114B2 (en) | 2011-03-08 | 2014-12-02 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
| US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7119104B2 (en) * | 2001-10-12 | 2006-10-10 | Nippon Chemiphar, Co., Ltd. | Activator of peroxisome proliferator-activated receptor delta |
| PA8594401A1 (es) * | 2003-02-21 | 2004-09-16 | Pfizer | Acidos carboxilicos de heteroarilo condensado como agonista del ppar |
-
2005
- 2005-08-27 CA CA002580135A patent/CA2580135A1/en not_active Abandoned
- 2005-08-27 JP JP2007530616A patent/JP2008512408A/ja not_active Abandoned
- 2005-08-27 CN CNA2005800304627A patent/CN101018790A/zh active Pending
- 2005-08-27 MX MX2007002689A patent/MX2007002689A/es not_active Application Discontinuation
- 2005-08-27 AU AU2005284485A patent/AU2005284485A1/en not_active Abandoned
- 2005-08-27 BR BRPI0515168-6A patent/BRPI0515168A/pt not_active IP Right Cessation
- 2005-08-27 KR KR1020077005673A patent/KR20070053243A/ko not_active Withdrawn
- 2005-08-27 EP EP05778246A patent/EP1794159B1/en not_active Expired - Lifetime
- 2005-08-27 WO PCT/EP2005/009269 patent/WO2006029699A1/en not_active Ceased
-
2007
- 2007-02-26 IL IL181560A patent/IL181560A0/en unknown
- 2007-03-05 US US11/681,923 patent/US7541464B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| MX2007002689A (es) | 2007-05-16 |
| JP2008512408A (ja) | 2008-04-24 |
| KR20070053243A (ko) | 2007-05-23 |
| IL181560A0 (en) | 2007-07-04 |
| EP1794159B1 (en) | 2012-08-01 |
| AU2005284485A1 (en) | 2006-03-23 |
| US20070254908A1 (en) | 2007-11-01 |
| CA2580135A1 (en) | 2006-03-23 |
| WO2006029699A1 (en) | 2006-03-23 |
| EP1794159A1 (en) | 2007-06-13 |
| CN101018790A (zh) | 2007-08-15 |
| US7541464B2 (en) | 2009-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0515168A (pt) | 7-azaindóis, processos para sua preparação e seu uso como fármacos | |
| Rossignol | Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus | |
| BR112021022796A2 (pt) | Inibidores de inflamassoma de nlrp3 | |
| BR122019010200B8 (pt) | compostos de pirazol-quinazolina, seus sais, produtos ou kits e composições farmacêuticas | |
| BRPI0517634A (pt) | derivado de tiazol ou um derivado farmaceuticamente aceitável do mesmo, processo para a preparação de um composto, composição farmacêutica, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição | |
| BR112013011634A2 (pt) | derivados de 2,3-di-hidroimidazol[1,2-c]quinazolina substituídos por aminoálcool úteis para tratar os distúrbios hiperproliferativos e as doenças associadas com a angiogênese derivados de 2,3-di-hidroimidazol[1,2-c] | |
| BRPI0514310A (pt) | 8-aminoalcóxi-xantinas substituìdas, método para a produção das mesmas e seu uso como medicamentos | |
| NO20081367L (no) | Fenyl- og pyridyl-1,2,4-oksadiazolonderivater med fenylgruppe, fremgangsmater for fremstilling derav og deres anvendelse som farmasoytika | |
| BR0317458A (pt) | EnanciÈmero-s, composto, formulação farmacêutica, método para tratar ou previnir distúrbios de lipìdeos (dislipdemia) associados ou não com resistência à insulina, uso de um composto, método para tratar ou previnir diabetes tipo 2, processo para a preparação de um composto, e, composição farmacêutica | |
| BRPI0412527A (pt) | composto, uso do mesmo, composição farmacêutica, formulação farmacêutica em aerossol, método para o tratamento de um paciente humano ou animal com uma condição anti-inflamatória e/ou alérgica, e, processo para preparar um composto. | |
| BRPI0510770A (pt) | derivados de fluorglicosìdeos de pirazóis, medicamentos contendo esses compostos e seu uso | |
| BR112013020605A2 (pt) | derivados de 6-ciclobutil-1,5-diidro-pirazol[3,4-d]pirimidin-4-ona e seu uso como inibidores de pde9a | |
| BRPI0615145A2 (pt) | derivados de xantina como agonistas hm74a seletivos | |
| Bonifácio et al. | Brain and peripheral pharmacokinetics of levodopa in the cynomolgus monkey following administration of opicapone, a third generation nitrocatechol COMT inhibitor | |
| BRPI0512075A (pt) | composto, processo para a preparação do mesmo, composição farmacêutica, uso de um composto, e, métodos para a produção de um efeito inibidor de b-raf, e de um efeito anticáncer em um animal de sangue quente, e para o tratamento de uma doença | |
| BRPI0719195B8 (pt) | inibidores de quinase, seus usos, e composição farmacêutica | |
| EA201201664A1 (ru) | Производные 6-циклоалкил-1,5-дигидропипазоло[3,4-d]пиримидин-4-она и их применение в качестве ингибиторов pde9a | |
| BRPI0613570B8 (pt) | composto, composição farmacêutica e uso de um composto ou um sal farmaceuticamente aceitável do mesmo | |
| BRPI0407907A (pt) | derivados de ácido alcánico substituìdos com aril-cicloaquila, processos para preparação dos mesmos e uso dos mesmos como medicamentos | |
| NO20081369L (no) | Fenyl- og pyridinyl-1,2,4-oksadiazolonderivater, fremgangsmate for deres fremstilling og deres anvendelse som farmasoytika | |
| BRPI0407901A (pt) | derivados de diarilcicloalquila, processos para preparação dos mesmos e uso dos mesmos como medicamentos | |
| BRPI0713132B8 (pt) | compostos derivados de cinamoil-piperazina, método de preparação dos referidos compostos, composições farmacêuticas, seus usos como antagonistas de par-i e produtos | |
| BRPI0518898A2 (pt) | composto, processo para sua preparaÇço, composiÇço farmacÊutica, mÉtodo para tratamento e uso do composto | |
| BRPI0414780A (pt) | composto, uso do mesmo, composição farmacêutica, e, métodos para a terapia da dor em um animal de sangue quente, e para preparar um composto | |
| BRPI0509517A (pt) | derivados de oxadiazolona como agonistas de ppar delta |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 7A ANUIDADE. |